公开(公告)号：US20180246105A1

公开(公告)日：2018-08-30

申请号：US15962776

申请日：2018-04-25

Applicant: FUDAN UNIVERSITY

Inventor： Bin WANG ,  Chaofan LI ,  Chenliang ZHOU ,  Xian ZHOU ,  Shuang WANG

IPC: G01N33/576 ,  G01N33/68 ,  G01N33/53 ,  G01N33/49

CPC classification number: G01N33/5761 ,  A61K39/12 ,  A61K2039/545 ,  A61K2039/55522 ,  A61K2039/57 ,  A61P31/20 ,  C12N2730/10122 ,  C12N2730/10134 ,  G01N33/4915 ,  G01N33/5304 ,  G01N33/56977 ,  G01N33/6857 ,  G01N2333/02 ,  G01N2333/70514 ,  G01N2333/70517 ,  G01N2333/70539

Abstract: Embodiments of the invention provide a cell immunological assay kit used for evaluating the efficacy of a vaccine on the aspect of cell immunology and a method for storing the cell immunological assay kit. Some embodiments of the invention comprise a MHC-restricted viral antigenic peptide. Further, in some embodiments, the kit may use a vaccine research database of clinical trials and samples which are utilized in the therapeutic and conduct comprehensive testing on immune cells secrete cytokines by flow cytometry to establish a cellular immunology evaluation system. The kit may have a good storage stability and, in particular embodiments, the kit may provide a stability that maintains more than 90% of a material stored therein over a year or more.

公开(公告)号：US20170327797A1

公开(公告)日：2017-11-16

申请号：US15661283

申请日：2017-07-27

Applicant: Hoffmann-La Roche Inc.

Inventor： Lu Gao ,  Hui Hu ,  Zhipeng Yan ,  Kunlun Xiang ,  Youjun Yu ,  Jing Zeng

IPC: C12N7/00 ,  C07K14/005 ,  G01N33/576 ,  C12Q1/70 ,  G01N33/50 ,  C12P19/34 ,  A01K67/027

CPC classification number: C12N7/00 ,  A01K67/027 ,  A01K2207/05 ,  A01K2227/105 ,  A01K2267/0337 ,  A61K49/0008 ,  C07K14/005 ,  C12N2730/10121 ,  C12N2730/10151 ,  C12N2800/30 ,  C12N2800/50 ,  C12N2800/80 ,  C12P19/34 ,  C12Q1/706 ,  C12Q2600/136 ,  G01N33/5088 ,  G01N33/5761 ,  G01N2333/02 ,  G01N2500/10

Abstract: The present invention relates to a recombinant HBV cccDNA comprising HBV genome or the fragment or variant thereof and a site-hybrid insert, a method to generate said recombinant HBV cccDNA, a method for establishment of an in vitro or in vivo cccDNA based model for persistently hepatitis B virus replication by using the recombinant HBV cccDNA of the present invention, and a method for anti-HBV drug evaluation.

公开(公告)号：US20170242010A1

公开(公告)日：2017-08-24

申请号：US15114262

申请日：2015-02-10

Applicant: The Regents of the University of California

Inventor： Ke-Qin Hu

IPC: G01N33/576 ,  C12Q1/70 ,  G01N33/543

CPC classification number: G01N33/5767 ,  C12Q1/707 ,  C12Q2600/158 ,  G01N33/54386 ,  G01N33/5761 ,  G01N2333/02 ,  G01N2800/26

Abstract: Disclosed herein are assays, systems, and kits for the detection and diagnosis of hepatitis virus infections in subjects.

公开(公告)号：US09334317B2

公开(公告)日：2016-05-10

申请号：US13511116

申请日：2010-11-19

Applicant: Antonio Bertoletti ,  Sastry Konduru Seetharama ,  Paul Anthony Macary ,  Soh Ha Chan ,  Chien Tei Too

Inventor： Antonio Bertoletti ,  Sastry Konduru Seetharama ,  Paul Anthony Macary ,  Soh Ha Chan ,  Chien Tei Too

IPC: C07K16/10 ,  C12N15/06 ,  C07H21/04 ,  A61K39/42 ,  C07K16/08 ,  G01N33/574 ,  G01N33/576

CPC classification number: C07K16/082 ,  C07K2317/32 ,  C07K2317/90 ,  G01N33/574 ,  G01N33/57407 ,  G01N33/5761 ,  G01N2333/02 ,  G01N2800/52

Abstract: There is provided at least one isolated TCR-like antibody or fragment thereof, wherein the antibody or fragment thereof is capable of specifically binding to at least one HBV derived peptide.

Abstract translation: 提供至少一种分离的TCR样抗体或其片段，其中所述抗体或其片段能够特异性结合至少一种HBV衍生肽。

公开(公告)号：US20120308580A1

公开(公告)日：2012-12-06

申请号：US13511116

申请日：2010-11-19

Applicant: Antonio Bertoletti ,  Sastry Konduru Seetharama ,  Paul Anthony Macary ,  Soh Ha Chan ,  Chien Tei Too

Inventor： Antonio Bertoletti ,  Sastry Konduru Seetharama ,  Paul Anthony Macary ,  Soh Ha Chan ,  Chien Tei Too

IPC: C07K16/10 ,  C12N15/06 ,  C07H21/04 ,  A61K39/42 ,  A61P31/14 ,  C12N5/16 ,  G01N33/569

CPC classification number: C07K16/082 ,  C07K2317/32 ,  C07K2317/90 ,  G01N33/574 ,  G01N33/57407 ,  G01N33/5761 ,  G01N2333/02 ,  G01N2800/52

Abstract: There is provided at least one isolated TCR-like antibody or fragment thereof, wherein the antibody or fragment thereof is capable of specifically binding to at least one HBV derived peptide.

Abstract translation: 提供至少一种分离的TCR样抗体或其片段，其中所述抗体或其片段能够特异性结合至少一种HBV衍生肽。

公开(公告)号：US20090017443A1

公开(公告)日：2009-01-15

申请号：US11596663

申请日：2005-05-19

Applicant: Chiharu Ohue ,  Noboru Maki ,  Tatsuji Kimura

Inventor： Chiharu Ohue ,  Noboru Maki ,  Tatsuji Kimura

IPC: C12Q1/70

CPC classification number: G01N33/5761

Abstract: To provide a method for detection or quantification of hepatitis B virus (HBV) antigens in serum and a simple and highly user-friendly method for sample treatment for use in the detection or quantification thereof. The method for treatment of a sample containing hepatitis B virus (HBV) is characterized in that release of HBV antigens and disruption of antibodies that bind to HBV antigens are carried out by treating a sample containing HBV with a treatment agent containing (1) an acidifying agent and (2) a protein denaturant or an amphoteric surfactant or cationic surfactant having an alkyl group and a tertiary amine or a quaternary ammonium salt within a molecule.

Abstract translation: 提供血清中乙型肝炎病毒（HBV）抗原的检测或定量的方法，以及用于检测或定量的用于样品处理的简单且高度用户友好的方法。 用于治疗含有乙型肝炎病毒（HBV）的样品的方法的特征在于通过用含有（1）酸化的处理剂处理含有HBV的样品来进行HBV抗原的释放和与HBV抗原结合的抗体的破坏 试剂和（2）分子内具有烷基和叔胺或季铵盐的蛋白质变性剂或两性表面活性剂或阳离子表面活性剂。

公开(公告)号：US20070054264A1

公开(公告)日：2007-03-08

申请号：US10578848

申请日：2004-10-22

Applicant: Ulla Hellstrom ,  Staffan Sylvan

Inventor： Ulla Hellstrom ,  Staffan Sylvan

IPC: C12Q1/70

CPC classification number: G01N33/5761 ,  G01N2469/20

Abstract: The present inventors have discovered that the presence of antibodies reactive with residues 94-117 of the PreS1 component of the hepatitis B surface antigen (HBsAg) in an individual with HBV infection correlates closely with the effectiveness of interferon (IFN) in treating the individual. Methods and means based on this finding are provided herein.

Abstract translation: 本发明人已经发现，在具有HBV感染的个体中，与乙型肝炎表面抗原（HBsAg）的PreS1组分的残基94-117反应的抗体的存在与干扰素（IFN）在治疗个体中的有效性密切相关。 本文提供了基于此发现的方法和手段。

公开(公告)号：US20020146686A1

公开(公告)日：2002-10-10

申请号：US10010943

申请日：2001-12-06

Applicant: Millennium Pharmaceuticals, Inc.

Inventor： W. James Cook ,  Rachel Meyers

IPC: C12Q001/70 ,  C12Q001/68 ,  C07H021/04

CPC classification number: C12Q1/6883 ,  C12Q2600/158 ,  G01N33/56983 ,  G01N33/56994 ,  G01N33/5761 ,  G01N33/5767 ,  G01N2333/916 ,  G01N2500/04

Abstract: The present invention relates to methods and compositions for the diagnosis and treatment of viral disease, including, but not limited to, herpes simplex virus, hepatitis B and hepatitis C viral infection. Specifically, the present invention identifies PLD 55092 genes which are differentially expressed in virus infected cells, relative to their expression in normal, uninfected cells. The present invention describes methods for the diagnostic evaluation and prognosis of various viral diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of viral disease, and for monitoring the efficacy of compounds in clinical trials. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of viral disease.

Abstract translation: 本发明涉及用于诊断和治疗病毒性疾病的方法和组合物，包括但不限于单纯疱疹病毒，乙型肝炎和丙型肝炎病毒感染。 具体地，本发明鉴定了在病毒感染的细胞中差异表达的PLD 55092基因相对于在正常未感染细胞中的表达。 本发明描述了用于各种病毒性疾病的诊断评价和预后的方法，以及用于鉴定表现出这种病症倾向的受试者。 本发明提供了用于诊断病人疾病进行临床评价的患者的诊断监测方法，以及用于监测化合物在临床试验中的功效的方法。 本发明还提供了鉴定和治疗化合物作为病毒性疾病治疗的方法。

公开(公告)号：US5863720A

公开(公告)日：1999-01-26

申请号：US501103

申请日：1995-10-27

Applicant: Richard Seton Tedder

Inventor： Richard Seton Tedder

IPC: G01N33/543 ,  G01N33/576 ,  C12Q1/70 ,  G01N33/53 ,  G01N33/566 ,  G01N33/569

CPC classification number: G01N33/5761 ,  G01N33/54306 ,  Y10S435/973

Abstract: By conducting two assays for related serological disease markers in a single vessel and arranging for one assay to give a signal which increases with increasing concentration of a first marker while the second assay gives a signal which decreases with increasing concentration of a second marker, and by balancing the respective sizes of the two signals, a combined signal can be generated which indicates the status of an individual or a blood donation with respect to the stage of recovery from the disease.

Abstract translation: PCT No.PCT / GB94 / 00298 Sec。 371 1995年10月27日第 102（e）日期1995年10月27日PCT 1994年2月15日提交PCT公布。 公开号WO94 / 18570 日期1994年8月18日通过在单个血管中进行相关血清学疾病标志物的两次测定，并安排一次测定以产生随着第一个标记物浓度增加而增加的信号，而第二次测定给出随着浓度增加而降低的信号 并且通过平衡两个信号的相应尺寸，可以产生组合信号，其表示相对于从疾病恢复的阶段的个体状态或献血状态。

公开(公告)号：US5534405A

公开(公告)日：1996-07-09

申请号：US342374

申请日：1994-11-18

Applicant: Ann M. Moriarty ,  Hannah Alexander ,  Richard A. Lerner

Inventor： Ann M. Moriarty ,  Hannah Alexander ,  Richard A. Lerner

IPC: G01N33/576 ,  A61K39/00 ,  A61K39/29 ,  C07K7/04 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07K14/02 ,  C07K14/10 ,  C07K14/18 ,  C07K16/00 ,  C07K16/08 ,  C12N1/00 ,  C12N5/00 ,  C12N5/10 ,  C12N15/00 ,  C12N15/09 ,  C12N15/51 ,  C12N15/86 ,  C12P21/00 ,  C12P21/02 ,  C12Q1/70 ,  C12R1/91 ,  G01N33/53 ,  G01N33/577

CPC classification number: C07K14/005 ,  C07K16/082 ,  C12N15/86 ,  C12Q1/706 ,  G01N33/5761 ,  A61K39/00 ,  C12N2730/10122 ,  Y10S435/975 ,  Y10S436/82 ,  Y10S530/826 ,  Y10S930/223

Abstract: Cloning and expression vectors for hepatitis B HBxAg, cell cultures containing those vectors, polypeptides related to HBxAg, and diagnostic systems and methods for assaying for the presence of HBxAg and anti-HBxAg antibodies in a body sample are disclosed.

Abstract translation: 公开了用于乙型肝炎HBxAg的克隆和表达载体，含有这些载体的细胞培养物，与HBxAg相关的多肽，以及用于测定身体样品中HBxAg和抗HBxAg抗体存在的诊断系统和方法。